advertisement

Concizumab (Alhemo) don Hemophilia A ko B tare da Masu hanawa

Concizumab (sunan kasuwanci, Alhemo), FDA ta amince da maganin rigakafi na monoclonal akan 20 Disamba 2024 don rigakafin cututtukan jini a cikin marasa lafiya tare da hemophilia A tare da factor VIII inhibitors ko hemophilia B tare da factor IX inhibitors. Ya sami izini daga Hukumar Kula da Magunguna ta Turai (EMA) kwanakin da suka gabata a kan 16 Disamba 2024 don alamun iri ɗaya.  

Wasu marasa lafiyar haemophilia a kan "magungunan abubuwan da ke haifar da clotting" don kula da yanayin rashin jinin jini suna haifar da ƙwayoyin rigakafi (a kan magungunan clotting factor). Kwayoyin rigakafin da aka kafa suna hana aikin "magungunan abubuwan da ke haifar da jini" yana sa su zama marasa tasiri. A halin yanzu ana kula da wannan yanayin ta hanyar haifar da juriya na rigakafi ta hanyar alluran abubuwan da ke damun jini a kullum. Amincewa da Concizumab (Alhemo) yana ba wa irin waɗannan marasa lafiya madadin magani.  

Ana gudanar da Concizumab kowace rana azaman allurar subcutaneous.  

Amincewa da Alhemo ya dogara ne akan kimanta amincinsa da ingancinsa a cikin ƙasashe da yawa, cibiya da yawa, buɗaɗɗen lakabin, gwaji na asibiti na lokaci 3. A cikin gwajin, an rage yawan adadin zubar jini na shekara-shekara (ABR) da kashi 86% na ƙungiyar jiyya na Alhemo idan aka kwatanta da ƙungiyar da ba ta da kariya.  

Rashin zubar jini a cikin haemophilia yana faruwa ne saboda rashin isassun abubuwan da ke damun jini. Haemophilia A yana faruwa ne saboda rashi na nau'in clotting factor VIII, yayin da haemophilia B ya kasance saboda ƙananan matakan factor IX. Rashin aikin factor XI yana da alhakin haemophilia C. Ana kula da waɗannan yanayi ta hanyar shigar da kayan aikin clotting na kasuwanci ko wani samfurin da ba shi da mahimmanci a matsayin maye gurbin aikin da ya ɓace.  

Octocog alfa (Advate), wanda shine 'wanda aka kirkira ta hanyar amfani da fasahar DNA' nau'in nau'in clotting factor VIII, ana amfani dashi akai-akai don rigakafi da kuma kan buƙatar magani na haemophilia A. Don haemophilia B, nonacog alfa (BeneFix), wanda sigar injiniya ce ta clotting factor IX da ake yawan amfani da ita.  

Hympavzi (marstacimab-hncq), wani ɗan adam monoclonal antibody wanda ke niyya "masu hana hanyar hanyar nama" kwanan nan an amince da su azaman sabon magani don rigakafin cututtukan jini a cikin mutanen da ke da hemophilia A ko hemophilia B.   

*** 

References:  

  1. FDA ta amince da magani don hanawa ko rage yawan adadin zub da jini ga marasa lafiya da ke da haemophilia A tare da masu hanawa ko haemophilia B tare da masu hanawa. An buga 20 Disamba 2024. Akwai a https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-prevent-or-reduce-frequency-bleeding-episodes-patients-hemophilia-inhibitors-or 
  1. EMA. Alhemo - Concizumab. Akwai https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo da kuma https://ec.europa.eu/health/documents/community-register/html/h1881.htm  
  1. NHS. Maganin Hemophilia. Akwai a https://www.nhs.uk/conditions/haemophilia/treatment/ 
  1. CDC. Maganin Hemophilia. Akwai a  https://www.cdc.gov/hemophilia/treatment/index.html 

Labari mai dangantaka 

*** 

Kungiyar SIEU
Kungiyar SIEUhttps://www.scientificeuropean.co.uk
Scientific European® | SIEU.com | Gagarumin ci gaba a kimiyya. Tasiri kan bil'adama. Hankalin zukata.

Biyan kuɗi zuwa da Newsletter

Don sabuntawa tare da duk sabon labarai, samarwa da sanarwa na musamman.

Shahararrun Labarai

PROBA-V Ya Kammala shekaru 7 a Orbit Yin Hidima ga Bil Adama

Tauraron dan Adam na Belgium PROBA-V, wanda Hukumar Kula da Sararin Samaniya ta Turai ta kera...

Za a iya Merck's Molnupiravir da Pfizer's Paxlovid, Sabbin Magungunan Anti-Viral guda Biyu akan COVID-19…

Molnupiravir, maganin baka na farko a duniya (MHRA ta amince,...

mRNA-1273: Alurar mRNA na Moderna Inc. Against Novel Coronavirus yana Nuna Sakamako Mai Kyau

Wani kamfanin fasahar halittu, Moderna, Inc. ya sanar da cewa 'mRNA-1273', ...
- Labari -
92,811FansKamar
47,297FollowersFollow
1,772FollowersFollow
30biyan kuɗiLabarai